Pipeline Insight: Hematological malignancies - Targeted treatments & immunotherapy

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2005-04-20

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Given an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche's Rituxan, it is no surprise that targeted treatments and immunotherapy dominate the pipeline. Integrating these novel technologies into existing treatment paradigms and demonstrating the 'value' of these high cost treatments will provide major challenges.


Scope

  • Overview of hematological malignancy market including patient segmentation, unmet needs and how novel therapies will alter existing treatment patterns
  • Profiles of key agents in late stage development including cytotoxics, immunotherapies and targeted treatments
  • Analysis of trial data, marketing factors and sales forecasts for key technologies in late-stage clinical development
  • Clinical, regulatory and pharmacoeconomic challenges and strategies for commercialization


    • Report Highlights
    Targeted therapies dominate the pipeline, constituting 47% of drugs in clinical development. The signal transduction inhibitors (STIs) dominate the MTT class. Focusing on STIs offers developers the potential to target drivers of oncogenesis that may exhibit commonality across a spectrum of hematological malignancies.

    Of the drugs in late-stage clinical development, Datamonitor is of the opinion that Chiron's Proleukin and MGI Pharma/ Supergen's Dacogen hold the greatest commercial potential with estimated peak sales by 2014 of $200m and $500m respectively

    While there is much hype surrounding the use of the MTTs for the pharmacotherapy of hematological malignancies, the cytostatic nature of some of these agents mean that it is likely that significant tumor regressions will more frequently be seen in context of combinatorial therapy employing traditional cytotoxic drugs.


    Reasons to Purchase

  • Understand unmet needs in the hematological malignancy market based on opinion leader comments regarding both currently marketed and pipeline products
  • Gain a greater understanding how future economic and regulatory constraints may affect approval for hematological malignancy drugs
  • Assess the global sales forecasts of late-stage pipeline drugs for hematological malignancies and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: myelodysplastic leukemia lymphoma malignancies haematological hematological malignancy bendamustine hematologic treatment targeted pipeline oncology

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.